Figure 3. . Receiver operating characteristics curve of HIF-1α percentage of tumor expression (area under the curve = 0.65) in patients with versus without RECIST-defined progression-free survival at 38 weeks after initial sunitinib dose.

HIF-1α cut-points = 1, 2 and 3 represent percent of tumor expression = 25, 50 and 75%, respectively. Red dotted line: theoretical perfect performance of an efficacy biomarker. Black solid line: theoretical performance of an efficacy biomarker equivalent to a coin toss. Blue line: actual performance of the HIF-1α percentage of tumor expression result at the prespecified cut-points.